Rosetta Genomics Buys CLIA Lab for $2.9M in Cash, Stock to Support miRNA Dx Efforts
Rosetta Genomics this week said that it has signed a binding term sheet to acquire Clinical Laboratory Improvement Amendments-certified laboratory Parkway Clinical Laboratories for $2.9 million in a bid to speed its introduction of microRNA-based diagnostics.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
